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Abstract
Although acquired mutations in KIT are commonly detected in various categories of mastocytosis, 
the methodologies applied to detect and quantify the mutant type and -burden in various tissues 
and cells are poorly defined. We here propose a consensus on methodologies used to detect KIT 
mutations in patients with mastocytosis at diagnosis and in the follow up with sufficient precision 
and sensitivity in daily practice. In addition, we provide recommendations for sampling and 
storage of diagnostic material as well as a robust diagnostic algorithm. Using highly-sensitive 
assays, KIT D816V can be detected in peripheral blood leukocytes in most patients with systemic 
mastocytosis (SM) which is a major step forward in screening and SM detection. In addition, the 
KIT D816V allele burden can be followed quantitatively during the natural course or during 
therapy in these patients. Our recommendations should greatly facilitate diagnostic and follow up 
investigations in SM in daily practice as well as in clinical trials. In addition, the new tools and 
algorithms proposed should lead to a more effective screen, early detection of SM, and help avoid 
unnecessary referrals.
Keywords
mast cell; mastocytosis; KIT; mutation; allele burden; allele specific PCR; classification; 
prognostication; monitoring of residual disease
Introduction
Mast cells (MCs) and their committed progenitors express KIT,{Krishnaswamy, 2006 #903} 
a transmembrane type III tyrosine kinase receptor also found in melanocytes, hematopoietic 
stem cells, germ cells and interstitial cells of Cajal.{Miettinen, 2005 #646} The ligand of 
KIT, stem cell factor (SCF), induces MC development from uncommitted and MC-
committed hematopoietic precursor cells.{Ashman, 2000 #337} In the human system, MC-
committed progenitors reside in the bone marrow (BM) and circulate in the peripheral blood 
(PB), whereas mature MCs usually are tissue-fixed non-circulating cells, found in virtually 
all vascularized organs.{Kirshenbaum, 1999 #549;Matarraz, 2008 #1493;Teodosio, 2010 
#91}
Mastocytosis is a rare and heterogeneous disease characterized by the accumulation of 
clonal MCs in one or multiple organs. The disease is mostly acquired, although rare familial 
cases have been described.{Chang, 2001 #389} Mastocytosis can affect both children and 
adults.{Valent, 2012 #1559} In most pediatric patients, the disease affects only the skin, 
with different types of lesions.{Briley, 2008 #370} In these cases, the disease is termed 
cutaneous mastocytosis, CM. In CM the biopsy of lesional skin reveals MC infiltration, 
sometimes with atypical MCs forming aggregates in local areas.{Vano-Galvan, 2011 
#1447} In children, the disease has a tendency to regress spontaneously,{Arock, 2010 #80} 
although some persist into adulthood.{Fried, 2013 #1466} By contrast, in most adult 
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patients, the disease is systemic and chronic and affects almost invariably the BM. These 
cases are called systemic mastocytosis, SM. In most patients, indolent SM (ISM) is 
diagnosed and the skin is affected.{Arock, 2010 #80} More aggressive subtypes of SM are 
rare and include aggressive SM (ASM) and MC leukemia (MCL). Depending on data-source 
and center, 5 to 20% of all SM patients present with or develop an associated clonal 
hematological non-MC-lineage disease (SM-AHNMD).{Wang, 2013 #39} Symptoms in 
mastocytosis may occur from diverse effects of mediators that are released from neoplastic 
MCs, and, in case of ASM or MCL, from organ infiltration by MCs, with subsequent 
organomegaly and/or organ damage.{Metcalfe, 2008 #641}
Patients with mastocytosis are diagnosed and classified according to the proposal of the 
World Health Organization (WHO) which distinguishes 7 categories of mastocytosis: 
cutaneous mastocytosis (CM), indolent systemic mastocytosis (ISM), SM with an associated 
clonal hematopoietic non MC disease (SM-AHNMD), agressive systemic mastocytosis 
(ASM), MC leukemia (MCL), MC sarcoma (MCS) and extracutaneous mastocytoma.
{Valent, 2001 #1646;Valent, 2001 #1490;Horny, 2008 #1449}. For some of these categories 
(CM, ISM, SM-AHNMD, ASM and MCL, subvariants have been identified, based on 
clinical and/or biological features.{Valent, 2001 #1646;Valent, 2001 #1490;Horny, 2008 
#1449} For patients with SM, the WHO has provided one major diagnostic criterion 
(infiltrates of >15 aggregated MCs identified through tryptase immuno-histochemistry or 
other stains in sections obtained from BM and/or other extracutaneous organ(s)) and four 
minor SM diagnostic criteria based on i) the presence of atypical MCs in lesional tissues, ii) 
the presence of an activating point mutation in codon 816 in KIT in BM, PB, or any 
extracutaneous organ, iii) the abberant expression of CD2 and or CD25 by neoplastic MCs 
and iv) a persistently elevated (> 20 ng/mL) serum tryptase level .{Valent, 2007 #1598} The 
diagnosis SM can be established when at least the major and one minor or three minor 
criteria are found.{Valent, 2007 #1598}
In adult patients, an activating KIT D816V mutation (Nucleotide sequence 5′-3′: agagTcatc, 
position 2247), located in the phosphotransferase domain (PTD) of the receptor is found in 
>80% of all cases. The exact percentages vary depending on disease subtypes (e.g., ISM vs. 
ASM) and cell source (e.g., BM vs. PB).{Garcia-Montero, 2006 #1665;Sanchez-Munoz, 
2011 #1494;Erben, 2014 #1659;Kristensen, 2014 #12} By contrast, a KIT mutation is found 
in skin biopsy samples in nearly 75% of affected children but only one third present with 
KIT D816V.{Bodemer, 2010 #96} Other KIT mutations found in childhood mastocytosis are 
mainly located in the extracellular domain of the receptor, the most frequently retrieved 
being a deletion at position 419 of the protein (Nucleotide sequence 5′-3′: acttac — aggctc, 
position 1255).{Bodemer, 2010 #96}
In most SM patients, particularly in ISM, the number of neoplastic MCs in the BM is low 
(low MC burden).{Tan, 2006 #143} Thus, the relatively low sensitivity of conventional 
PCR in combination with sequencing of PCR products may result in false-negative cases. 
Indeed, in these patients, the median level of KIT D816V mutant alleles (also referred as to 
“KIT D816V allele burden”), is often below 1%, as measured by recently developed allele-
specific quantitative PCR assays, that are based on either DNA or on RNA/cDNA (ASO-
qPCR), but have a similar (high) sensitivity.{Kristensen, 2012 #59;Erben, 2014 
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#1659;Hoermann, 2014 #4} In addition, although rarely seen, SM patients may present with 
KIT mutations other than D816V, e.g., D816H, D816Y, or even mutations outside the PTD 
of KIT.{Bibi, 2014 #5} The latter can only be detected by PCR assays that are not routinely 
used, e.g., RFLP or HPLC of PCR products, but not by ASO-qPCR.{Valent, 2005 
#1621;Erben, 2014 #1659}
Recent reports using ASO-qPCR (on DNA or RNA/cDNA) have shown correlations 
between KIT D816V allele burden and clinical parameters such as disease subtype, 
prognosis and survival.{Escribano, 2009 #419;Erben, 2014 #1659;Hoermann, 2014 #4} 
Moreover, serial measurements of the KIT D816V allele burden by these ASO-qPCR 
techniques appear useful for monitoring of residual disease in aggressive subtypes during or 
after cytoreductive therapy or allogeneic stem cell transplantation.{Erben, 2014 
#1659;Hoermann, 2014 #4}
The present article provides consensus recommendations from members of the European 
Competence Network on Mastocytosis (ECNM{Valent, 2004 #1616;Valent, 2012 #1548}) 
for standardized approaches and techniques to detect KIT mutations and to measure KIT 
mutant burden as part of the routine diagnostic work-up, prognostication and follow-up 
during or after treatment in patients with mastocytosis. Consensus recommendations have 
been developed and discussed among co-authoring members of the ECNM between 
September 2013 and September 2014. Consensus statements were discussed until complete 
consensus (all experts agreed) was reached (or not reached by September 2014) and only 
those consensus statements where complete consensus was reached have been included as 
such in the current article. Other points of discussions are labeled as open issues (under 
discussion or still under development) in our consensus document.
Short overview on the spectrum of KIT mutations and their clinical 
implications
KIT is encoded by a 21 exon-containing gene located on human chromosome 4q12.{Giebel, 
1992 #454} The resulting 976 amino acid-containing receptor has a molecular weight of 145 
kDa.{Chabot, 1988 #1452} A schematic representation of wild type KIT (KIT WT) is 
shown in Figure 1. The receptor is composed of an extracellular domain (ECD), a 
transmembrane domain (TMD), a juxtamembrane domain (JMD) and a tyrosine kinase 
domain (TKD). The TKD contains an ATP-binding site and a phosphotransferase domain 
(PTD) (Figure 1). A few single nucleotide polymorphisms (SNPs) which might account for 
susceptibility to various diseases have been described in the KIT gene.{Cheng, 2013 #1677} 
The most common SNP found in the KIT gene in human is an ATG to CTG transition in 
codon 541 (exon 10) giving rise to a M541L KIT protein sequence variation, which seems to 
confer increased sensitivity to the KIT ligand (SCF), although the clinical impact of this 
SNP remains unclear.{Nagata, 1996 #1675}
Activating mutations in KIT were first described in SM patients,{Longley, 1996 #612} and 
more recently in children with CM.{Bodemer, 2010 #96} In adult patients with ISM, ASM 
or SM-AHNMD, these mutations affect mainly the PTD of KIT, encoded by exon 17, 
usually at position 816 (most commonly KIT D816V),{Orfao, 2007 #129} whereas in 
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children, ECD mutants are also found.{Bodemer, 2010 #96} In MCL, the presence of the 
KIT D816V mutation seems less frequent than in other categories of SM.{Georgin-Lavialle, 
2013 #44} Finally, in the rare cases of familial mastocytosis, often presenting as pediatric 
CM, most cases exhibit no KIT mutations or uncommon germline mutations.{Zhang, 2006 
#161;Wasag, 2011 #71;Hoffmann, 2008 #497;Wohrl, 2013 #1465;Pollard, 2014 #1674} 
However, even somatic KIT mutations have been described in familial mastocytosis.
{Bodemer, 2010 #96;Broesby-Olsen, 2012 #56;Zanotti, 2013 #43} The Figure 2 presents all 
current KIT mutations retrieved in the literature for adult and children patient, together with 
their approximate frequencies.
SM-AHNMD (5 to 20% of all SM cases) is a special subvariant of the disease.{Wang, 2013 
#39} In most patients, an associated myeloid neoplasm is diagnosed, such as chronic 
myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), 
myelodyspastic/myeloproliferative neoplasm unclassifiable (MDS/MPN), MDS, chronic 
eosinophilic leukemia (CEL), AML or infrequently BCR-ABL1-positive MPN or MPN-
unclassifiable.{Sperr, 2002 #259;Stoecker, 2012 #1459;Wang, 2013 #39;Valent, 2013 
#36;Piazza, #1492} By contrast, lymphoid variants of AHNMD (multiple myeloma, B-cell 
lymphoma, chronic lymphocytic leukemia) are rarely found.{Sperr, 2002 #259;Stellmacher, 
2004 #1627;Horny, 2006 #1608} Interestingly, a recent study of 48 SM-AHNMD patients 
has shown that the KIT D816V mutation can be detected in almost all these individuals 
except those with SM with an associated CEL.{Sotlar, 2010 #1573} In most patients with 
SM-CMML, KIT D816V is detectable in AHNMD cells, suggesting the involvement of a 
common myelomono- and mastocytic precursor. In patients with SM-MPN and SM-AML, 
the KIT mutant D816V is also detectable, albeit at a lower frequency.{Fritsche-Polanz, 2010 
#1661;Fritsche-Polanz, 2010 #1661} Finally, in patients with lymphoproliferative 
AHNMDs, the AHNMD cells are usually negative for KIT 816.{Garcia-Montero, 2006 
#1665;Sotlar, 2010 #1573} Table 1 shows the frequency and distribution of the different 
KIT mutations in the diverse subtypes of mastocytosis based on current knowledge and 
recently published data.{Bibi, 2014 #5}
For each SM patients, the precise knowledge of the structure of KIT in neoplastic cells is of 
great clinical significance since the A-loop mutations D816V/H/Y/N induce resistance to 
imatinib in vitro as well as ex vivo in patients’ cells,{Frost, 2002 #184;Lasota, 2007 #580} 
This resistance has been attributed to the fact that the KIT D816V mutant disrupts the 
structure of the receptor, leading permanently to an active conformation, which cannot be 
targeted by imatinib.{Foster, 2004 #1676;Laine, 2011 #70} This resistance of the most 
common KIT mutant against imatinib found in SM, has led to the use of non-targeted 
cytoreductive therapy, such as cladribine (2CdA),{Kluin-Nelemans, 2003 #564} or 
interferon-α,{Hauswirth, 2004 #490} and to clinical trials with novel tyrosine kinase 
inhibitors (TKIs) that overcome resistance in these patients, such as PKC412 (midostaurin) 
with encouraging results.{Gotlib, 2010 #1483;Gotlib, 2012 #1484}} By contrast, the rare 
SM patients presenting with a KIT mutant outside the PTD (e.g. JMD or ECD mutants), or 
with no KIT mutation may respond to imatinib. {Zhang, 2006 #161;Hoffmann, 2008 
#497;Mital, 2011 #76;Alvarez-Twose, 2012 #1485}
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Recommendations for cells and assays to be used for KIT mutation 
analysis
This section will first describe the differences in the management between pediatric and 
adult patients. We will then highlight the various samples and cell types to be used for 
detection of KIT mutations in different subtypes of mastocytosis, as well as the different 
techniques used for this purpose, their advantages and possible limitations. Finally, we will 
provide recommendations for the most appropriate procedures to be applied at time of 
diagnosis and during follow-up.
Pediatric mastocytosis
In childhood patients with CM, BM investigations are usually not required unless clinical 
findings and symptoms suggest the presence of a relevant (aggressive) systemic disease.
{Fried, 2013 #1466} In the latter case, a thorough BM examination is recommended, 
including KIT mutation analysis.{Valent, 2007 #1598} In some patients in whom the 
diagnosis CM is in question because of atypical skin lesions and/or a questionable histology, 
lesional skin can be examined for the presence of KIT mutations.{Bodemer, 2010 #96} 
However this test is not regarded as standard in typical CM, which may change in the future, 
especially if it appears that the presence of a particular mutation is associated with a certain 
prognosis or with disease persistence into adulthood. In some of these cases, sequencing of 
the entire KIT coding region may be required and should be performed according to standard 
methodologies.{Bodemer, 2010 #96}
Adult patients
In SM, neoplastic MCs usually reside in the BM but are not found in the PB.
{Krishnaswamy, 2006 #903} Therefore, it has been standard to examine BM cells for the 
presence of KIT D816V.{Valent, 2014 #1529} Until recently, the most frequently used 
assay for the detection of KIT mutations has been conventional sequencing of PCR-derived 
amplicons. However, the level of sensitivity of this technique is rather low (10-20%) which 
may lead to false-negative results, especially when the degree of BM infiltration is low.
{Corless, 2006 #141} Consequently, considerable efforts have been made recently to 
improve assay sensitivities using different approaches, including PCR amplification 
followed by restriction digestion (PCR+RFLP),{Tan, 2006 #143} peptide nucleic acid 
(PNA)-mediated PCR clamping,{Sotlar, 2003 #1671} nested RT-PCR followed by 
denaturing high-performance liquid chromatography (DHPLC),{Erben, 2014 #1659} and 
ASO-qPCR assays.{Schumacher, 2008 #132;Kristensen, 2011 #77;Erben, 2014 
#1659;Kristensen, 2014 #12} More sophisticated techniques, including enrichment of MCs 
and other cell types from BM samples via laser micro-dissection or fluorescence-activated 
cell sorting (FACS) followed by PNA-mediated PCR-clamping technique, are used for 
research purposes but are not routinely used for diagnostic algorithms in most centers.
{Sotlar, 2000 #1673;Sotlar, 2002 #1672;Sotlar, 2003 #1671;Escribano, 2009 
#419;Teodosio, 2012 #66}
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Recommended tissues and cells for KIT mutation analysis
While it is generally recommended that fresh samples should be used whenever possible, 
storage of cells and isolation of total RNA or DNA from stored cells is also acceptable, 
provided that standard-methods are applied: cell suspensions should be stored in liquid 
nitrogen, extracted RNA should be stored at −70°C (or as cDNA at or below −20°C) and 
DNA at or below −20°C.
In suspected SM, the diagnostic standard is to examine unfractionated BM cells (after 
erythrocyte-lysis) or mononuclear marrow cells (MNC) for KIT mutations.{Valent, 2007 
#1598} The marrow aspirate (1-2 mL) should be recovered in EDTA or in heparin. In 
certain circumstances, when no BM aspirate sample is available, KIT mutational analyses 
can be performed on cells detached from BM smears or from a paraffin-embedded biopsy 
sample, provided that the procedure used to determine the KIT mutational status exhibits 
sufficient sensitivity.{Sotlar, 2013 #1660} A practical issue here is that if marrow aspirate is 
not obtainable, the core biopsy preservative should be formalin, and not Zencker’s or 
Bouin’s which degrades DNA.
In typical ISM, MNCs from peripheral blood (PB) are frequently KIT D816V negative when 
investigated by low sensitivity techniques, such as sequencing of PCR-derived amplicons. 
However, recent studies using ASO-qPCR-assays have suggested the possibility of detecting 
the mutation in PB in nearly all adult patients with typical SM.{Kristensen, 2014 #12;Erben, 
2014 #1659;Hoermann, 2014 #4} Thus, we recommend the use of such technique in PB 
samples as a screening test in cases with suspected SM.{Valent, 2014 #1529} However, the 
KIT D816V mutation may not be detected in all patients with SM by this approach, 
especially in the few cases where other mutations in KIT are present or the MC burden is 
extremely low. Therefore, we recommend testing of PB cells for initial screening, whereas a 
more detailed analysis must always include a thorough examination of the BM. Because of a 
variable burden of MCs it is recommended to either use a very sensitive technology for 
mutation-detection (e.g. ASO-qPCR),{Erben, 2014 #1659;Kristensen, 2014 #12} or to 
perform sequencing studies on MCs purified by laser microdissection or flow cytometry.
{Sotlar, 2000 #1673;Garcia-Montero, 2006 #1665} However, most centers have focused on 
developing sensitive ASO-qPCR assays rather than methods to purify MCs. It is important 
to note that every center establishing these tests should focus carefully on the possibility of 
false positive results by examining an appropriate number of negative controls.{Mattocks, 
2010 #1491}
Regarding adult patients with skin lesions (also referred as to “mastocytosis in the skin”, 
MIS), a skin biopsy can be performed, where the presence of KIT D816V is thus indicative 
for MIS.{Arock, 2010 #80} Nonetheless, this result is not diagnostic for systemic disease 
(SM) which still requires the demonstration of the presence of KIT D816V in the BM or PB.
{Valent, 2014 #1529} In addition, other visceral organs, such as the spleen, liver, GI tract or 
lymph nodes, may be affected in SM.{Travis, 1988 #1470;Diebold, 1991 #1469;Metcalfe, 
1991 #637;Horny, 1992 #281;Mican, 1995 #645;Horny, 1997 #272;Smith, 1999 
#1468;Jensen, 2000 #527} However, we do not recommend routine screening of these 
organs for the presence of KIT mutations. Involvement of a single extramedullary (visceral) 
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organ in SM in the absence of BM involvement is an extremely rare condition.{Parwaresch, 
1985 #695;Horny, 1985 #292} In such exceptional cases, it has been demonstrated that KIT 
mutations may also be detected in the involved organs.{Jensen, 2000 #527;Wimazal, 2004 
#1668}
Standard assays for detection of KIT D816V
Several assays for detection of the KIT D816V mutation have been reported. Based on 
literature-data, the most sensitive assays, briefly described below, are i) RT-PCR plus 
restriction fragment length polymorphism (RFLP), ii) nested RT-PCR followed by D-HPLC 
of PCR amplicons, iii) PNA-mediated PCR, and iv) ASO-qPCR on DNA or RNA/cDNA. 
These techniques should be regarded as standard, provided that they have sufficient 
specificity, sensitivity and precision. We thus recommend performing these techniques 
according to published protocols.{Fritsche-Polanz, 2001 #1448;Sotlar, 2003 #1671;Garcia-
Montero, 2006 #1665;Bodemer, 2010 #96;Kristensen, 2011 #77;Kristensen, 2012 
#59;Sotlar, 2013 #1660;Kristensen, 2014 #12;Erben, 2014 #1659} The advantages, 
disadvantages and sensitivity of the different tests recommended are summarized in Table 2.
RT-PCR and RFLP—The sensitivity of this technique allows the detection of one KIT 
D816V+ cell among 2000 KIT WT cells (0.05%).{Valent, 2007 #1598} However, the 
technique has limitations since it does not allow the detection of other mutations in codon 
816, and it is not quantitative.{Valent, 2007 #1598}
Nested RT-PCR followed by D-HPLC of PCR amplicons—The major interest of this 
technique is that it allows detection of all mutations in the amplified region and would be 
perfect for simultaneous detection of KIT D816V or of other mutations in codon 816 in the 
same reaction.{Erben, 2014 #1659} The technique has been optimized by the authors to 
detect mutant KIT D816V down to 0.5–1 % of mutant in normal cells based on cell line and 
RNA dilutions.{Erben, 2014 #1659}
Peptide nucleic acid-mediated (PNA)-mediated PCR—Three interesting features of 
this technique are that i) it allows detection of the mutated KIT D816V allele in a 1000-fold 
excess of WT background,{Sotlar, 2003 #1671} ii) it allows the identification of other 
mutations in codon 816 or in adjacent codons,{Sotlar, 2013 #1660} iii) it is the 
recommended method to be applied on formalin-fixed paraffin-embedded BM trephine 
biopsies.{Sotlar, 2003 #1671;Garcia-Montero, 2006 #1665;Sotlar, 2013 #1660}
Allele specific PCR (ASO-PCR) and ASO-quantitative PCR (ASO-qPCR)—ASO-
PCR is a simple, fast and reliable method to detect specifically the KIT D816V mutant in 
various tissues.{Schumacher, 2008 #132} Interestingly, the quantitative variant of the 
method (ASO-qPCR) has the advantage to allow simultaneously detection and allele burden 
measurement of KIT D816V in different tissues and cells (PB, BM and organ biopsies) at 
low cost (reagents <US $50).{Kristensen, 2011 #77;Kristensen, 2012 #59;Kristensen, 2014 
#12} As an example, Kristensen et al. presented recently an assay that detects less than 
0.01% KIT D816V mutation-positive cells.{Kristensen, 2011 #77} In their study, the 
authors analyzed a total of 61 samples derived from 31 cases diagnosed with various SM 
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subtypes and were able to detect the mutation in 95% of BM and 81% of PB samples, 
respectively.{Kristensen, 2011 #77} The Danish group further confirmed the sensitivity and 
reliability of their assay on lesional skin biopsies with positive results in all out of 29 adult 
SM patients.{Kristensen, 2013 #27} In another study conducted on 25 ISM patients, the 
same authors showed that the method detects the KIT mutant in circulating PB cells even if 
no circulating MCs are detectable.{Kristensen, 2012 #59} From these data, the group 
proposed adopting mutation analysis of PB as a “routine” diagnostic screen test in 
mastocytosis.{Kristensen, 2014 #12} The sensitivity and specificity of the ASO-qPCR 
analysis of PB cells was also examined. For this purpose, the authors analyzed PB samples 
in a total of 83 SM patients and 4 CM patients as well as 10 patients with a provisional 
diagnosis of MIS.{Kristensen, 2014 #12} In this study, KIT D816V was detected in 94% of 
all cases with SM. Interestingly, all 10 patients with MIS tested positive in this study, 
demonstrating the high sensitivity of the test in suspected SM.{Kristensen, 2014 #12} Based 
on this study and similar data from other centers,{Hoermann, 2014 #4;Erben, 2014 #1659} 
the ECNM suggests that PB should be used for the initial screening of KIT mutations in 
suspected SM patients in daily practice.{Valent, 2014 #1529} However, an issue is that in 
case of very low numbers of clonal MCs, the KIT D816V mutation may not be detectable in 
PB. Therefore, BM cells need to be investigated in all cases with high suspicion of SM. 
Finally, concerning the ASO-qPCR, multi-center standardization projects (ring trials) aimed 
at inter-center validation as well as harmonization will be required in the future.
Usefulness of allelic burden measurements of KIT D816V in PB and BM
Very recent reports have shown that allele burden measurement of KIT D816V in BM and 
PB using sensitive ASO-qPCR on DNA or on RNA/cDNA are not only useful for diagnostic 
purposes but also for prognostication, follow-up of the disease as well as for quantification 
of response to treatment such as chemotherapy or allogeneic SCT.{Erben, 2014 
#1659;Hoermann, 2014 #4}
Indeed, Hoermann and colleagues quantified the KIT D816V allele burden from genomic 
DNA derived from BM aspirates and PB by ASO-qPCR in a cohort of 105 patients with 
mastocytosis, including cases with CM (n=12), MIS (n=3), ISM (n=67), SSM (n=5), ASM 
(n=7), SM-AHNMD (n=10) and MCL (n=1).{Hoermann, 2014 #4} Interestingly, the 
authors reported significant differences in the median allele burden between disease 
subgroups, with an increased burden found in advanced disease: CM (0.042%), ISM 
(0.285%), SSM (5.991%), ASM (9.346%), and SM-AHNMD (3.761%). Confirming 
previous data,{Kristensen, 2013 #35} the authors also reported a good correlation between 
the KIT D816V allele burden and the serum tryptase levels. However, no significant 
correlation was found between the allele burden and the MC infiltration in the BM, which 
may be explained by the fact that non-MC-lineage cells in the BM also harbor KIT D816V, 
but at levels that may greatly vary from patient to patient.{Hoermann, 2014 #4} Moreover, 
the authors were able to demonstrate that the KIT D816V allele burden was of prognostic 
significance. In fact, patients with ISM showed a stable allele burden during the follow-up, 
whereas in case of progression, a marked increase in KIT D816V was found.{Hoermann, 
2014 #4} Finally, the authors were able to show that the KIT D816V allele burden decreases 
during cytoreductive therapy.{Hoermann, 2014 #4}
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In a similar study, Erben and colleagues used a KIT D816V ASO-qPCR on RNA/cDNA to 
diagnose mastocytosis and to monitor the allele burden as marker of residual disease.{Erben, 
2014 #1659} The SM patients analyzed (n=147) were classified as follows: ISM (n=63), 
SSM (n=8), SM-AHNMD (n=16) and ASM/MCL±AHNMD, (n=60). In 62 patients, 
samples were collected from BM and PB (ISM, n=28; SSM, n=4; SM-AHNMD, n=5; ASM/
MCL, n=25). Thus, overall, 210 samples were analyzed.{Erben, 2014 #1659} The authors 
observed that when compared to nested RT-PCR followed by HPLC and sequencing, their 
ASO-qPCR was more sensitive, detecting 0.01-0.1% of mutated cells. Independent of 
disease subtype, they identified the KIT D816V mutation in 97% of BM samples and in 78% 
of all PB samples tested.{Erben, 2014 #1659} In addition, they showed a strong correlation 
between the KIT D816V allele burden, disease subtype (e.g., indolent vs. advanced SM) and 
survival.{Erben, 2014 #1659} In terms of monitoring residual disease, the analysis was 
performed on 4 ASM/MCL±AHNMD patients treated either with cladribine (1 patient), 
aggressive chemotherapy (1 patient) or allogeneic SCT (2 patients). The authors reported a 
significant reduction of the KIT D816V allele burden in the BM and PB during treatment.
{Erben, 2014 #1659}
Thus, it appears that ASO-qPCR assays on DNA or on RNA/cDNA are highly sensitive 
methods for the quantification of the KIT D816V burden, and possibly preferable to nested 
PCR plus RFLP. Consequently, the ECNM recommends the use of the KIT D816V ASO-
qPCR assays for the analysis of patients with suspected SM in PB and BM samples in 
routine screening tests.{Valent, 2007 #1598} However, a few issues remain to be solved for 
the future. Indeed, neither of the ASO-qPCR assays can detect other mutations at codon 816 
of KIT (such as D816Y or D816H) or at positions outside the kinase domain.{Erben, 2014 
#1659;Kristensen, 2011 #77}
Guidelines to search for and monitor KIT D816V+ SM
RT-PCR+RFLP, PNA-mediated PCR, and ASO-qPCR are fast, reliable, sensitive, and cost-
effective methods for routine screening of KIT D816V in all SM subtypes. When applied on 
BM cells, all these assays have demonstrated their ability to detect the KIT D816V mutation 
in > 80% of SM patients, a sensitivity considered sufficient in daily practice.{Valent, 2007 
#1598} In addition, it has emerged that PB is sufficient for mutation analysis in many 
patients when the most sensitive assays are applied.{Erben, 2014 #1659;Hoermann, 2014 
#4;Valent, 2014 #1529} Thus, we propose to use KIT D816V ASO-qPCR assays in PB in 
combination with measurement of serum tryptase and other relevant parameters, such as 
specific clinical symptoms indicating potential organ involvement, for the routine screening 
of adult patients with suspected mastocytosis, and these recommendations are summarized 
in a algorithm for the diagnostic of adult patients with suspected mastocytosis (Figure 3). In 
addition, Table 3 describes the usefulness of KIT D816V ASO-qPCR assays, together with 
several other clinical, biological, molecular and radiographic explorations, in the diagnosis 
and monitoring of the disease. However, the applied methodology should be validated 
carefully with respect to the expected diagnostic yield which can be reduced dramatically by 
even minor reductions in sensitivity.{Kristensen, 2014 #12} Thus, KIT mutational analysis 
in BM samples may be always performed following a positive test on PB samples, and 
should be considered in cases with high suspicion of SM even when no KIT mutation is 
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detectable in the PB. In addition, the frequency of measurement of the allele burden should 
be adapted to the individual situation in each patient. Thus, in ISM patients with low MC 
burden and stable clinical course, the KIT D816V allele burden should be measured at 
diagnosis, but should not necessarily be repeated, unless signs of disease progression occur. 
In patients with more aggressive forms enrolled in clinical trials with cytoreductive 
therapies, the KIT D816V allele burden should be measured repeatedly before and during 
therapy.
Recommendations for SM cases with a “negative” KIT D816V test result
In a small percentage of cases (<5-10%) no mutation is detectable in codon 816 of KIT,
{Garcia-Montero, 2006 #1665;Sanchez-Munoz, 2011 #1494} which may have several 
explanations: i) patients are in fact KIT D816V+ but the (very) low MC burden leads to a 
false negative result because the sensitivity of the applied assay is too low, ii) patients 
indeed only bear wild type KIT or iii) patients are positive for other mutations at codon 816 
(D816H, D816Y, others) or in other regions of KIT which are not detectable by the ASO-
qPCR assays for KIT D816V. In scenario i) a KIT mutation may only be detected in highly 
enriched (sorted or microdissected) MCs or by using one of the highly sensitive techniques 
presented above.{Sotlar, 2003 #1671;Garcia-Montero, 2006 #1665;Kristensen, 2011 
#77;Erben, 2014 #1659;Hoermann, 2014 #4} However, enrichment is usually not required 
for decision-making in daily clinical practice as demonstration or exclusion of KIT D816V 
has no therapeutic consequence.
By contrast, in patients with ASM or MCL (huge MC-infiltrates), a negative screen-result is 
a diagnostic challenge. In such cases, certain KIT mutations in the JMD, TMD or ECD 
domains or even KIT wild-type may be excellent candidates for targeted treatment with 
imatinib,{Frost, 2002 #184;Akin, 2004 #315;Yang, 2010 #1451;Mital, 2011 #76;Georgin-
Lavialle, 2012 #63;Alvarez-Twose, 2012 #1485} whereas KIT D816V (and other mutations 
at position 816) are imatinib-resistant,{Valent, 2010 #81;Mital, 2011 #76;Georgin-Lavialle, 
2012 #63;Ashman, 2013 #1471} leading to the use of other TKIs with a broader activity, 
such as PKC412 (midostaurin),{Gotlib, 2010 #1483;Gotlib, 2012 #1484;Gleixner, 2013 
#38} or of non-targeted therapies such as Interferon-alpha, cladribine or allogeneic SCT.
{Kluin-Nelemans, 1992 #563;Kluin-Nelemans, 2003 #564;Ustun, 2014 #1498} Therefore, a 
negative result should be confirmed, preferably in a reference laboratory, by using the most 
sensitive technique available today, i.e. ASO-qPCR. This is then followed by examination of 
KIT for other mutations in codon 816, which requires amplification of the codon 17 and 
sequencing of the resulting amplicons or preferably PNA-mediated PCR.{Garcia-Montero, 
2006 #1665} Finally, if no mutation is found at codon 816, sequencing of the whole KIT 
coding sequences should be considered.{Bodemer, 2010 #96}
Concluding remarks and future perspectives
Highly sensitive and specific PCR-based assays for the detection of KIT D816V are now 
available. These methods have become standard in the routine screening of patients with 
suspected SM. Furthermore, quantification of the KIT mutational load may be rapidly 
adopted as gold standard for assessing the disease burden in advanced SM, thereby 
improving prognostication and monitoring of the disease course prior, during and after 
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cytoreductive therapies, including KIT-targeting drugs and allogeneic SCT. However, 
although more than 80% of all SM patients harbor KIT D816V, SM is a heterogeneous 
disease regarding mutational patterns, course and aggressiveness. It has also been shown 
that additional genetic lesions such as mutations in TET2, SRSF2, ASXL1, SRSF2 or RUNX1 
are frequently identified in patients with advanced SM, preferably in ASM or MCL with 
AHNMD.{Bibi, 2014 #5;Soucie, 2014 #1487;Schwaab, 2013 #1542} These lesions might 
decisively contribute to the clinical heterogeneity and the aggressiveness of SM and may 
represent new therapeutic targets. Thus, methods such as myeloid gene mutation panels, e.g. 
20-50 genes being evaluated in parallel, or next generation sequencing (NGS), applied on 
the whole genome, will allow the mapping of additional functionally important molecular 
lesions, which may complement or even replace present techniques used for KIT mutation 
analyses as basis to improve our knowledge about the clinical course of patients with 
mastocytosis.
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Figure 1. Structure of normal KIT (KIT Wild-Type)
The KIT gene, located on chromosome 4q12 in humans, contains 21 exons transcribed/
translated into a transmembrane receptor tyrosine kinase (RTK) of 145 kDa and 976 amino 
acids. KIT structure is characterized by 5 Ig-like subunits in the extracellular domain (ECD) 
which contains a ligand binding site (SCF for KIT) and a dimerization site, and is linked to a 
cytoplasmic region by a single transmembrane helix. The cytoplasmic region of KIT 
consists of an autoinhibitory juxta-membrane domain (JMD) and a kinase domain (KD) 
arranged in a proximal (N−) and a distal (C−) lobe linked by a hinge region. The C-lobe of 
RTKs type III includes a large Kinase Insert Domain (KID) of ~ 60-100 residues. The red 
star represents the position 816 where an Asp to Val point mutation (KIT D816V) is found 
in > 80% of adult systemic mastocytosis patients. The receptor is presented under its 
monomeric form, whereas a dimer results from stem cell factor (SCF) ligation. ECD: 
Extracellular domain; JMD: Juxtamembrane domain; KID: Kinase insert domain; PTD: 
phosphotransférase domain; TK: tyrosine kinase; TMD: transmembrane domain.
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Figure 2. Representation of the structure of KIT, illustrating the localization of the more 
frequently observed mutations in the KIT sequence in pediatric and adult patients with 
mastocytosis
The receptor is presented under its monomeric form, whereas its wild-type counterpart 
dimerizes upon ligation with SCF before being activated in normal cells. In children,he KIT 
D816V PTD mutant (in red) is found in nearly 30% of the patients, whereas the ECD 
mutants (in blue) are found in nearly 40% of the affected children. In adults, depending of 
the categoty of mastocytosis, the KIT D81V mutant is found in at least 80% of all patients. 
The complete list of KIT mutants retrieved in the literature for mastocytosis is depicted here. 
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In children, the structure of KIT is found WT in around 25% of the patients analyzed, 
whereas in adults, KIT is found WT in less than 20% of all patients analyzed so far. Some of 
the mutations (in black) are found only in a very few number of patients. Del: deletion; 
ECD: Extracellular domain; Ins: Insertion; ITD: Internal tandem duplication; JMD: 
Juxtamembrane domain; KI: Kinase insert; PTD: phosphotransferase domain; TMD: 
Transmembrane domain. ±: mutation found in less than 1% of the patients; +: mutation 
found in 1 to 5% of the patients; ++: mutation found in around 30% of pediatric patients and 
in > 80% of all adult patients.
Arock et al. Page 20
Leukemia. Author manuscript; available in PMC 2015 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Proposed algorithm for the use of KIT D816V allele-specific quantitative PCR or RT-
PCR (ASO-qPCR) in peripheral blood (PB), together with serum tryptase measurement, for the 
screening of adult patients with suspected mastocytosis
In case of suspected mastocytosis in an adult patient, the first step is the search for clear 
signs of mastocytosis in the skin (MIS). If MIS is present, we recommend that a BM 
examination should be performed directly. If there is no MIS, we recommend to measure 
serum tryptase level, together with a KIT D816V ASO-qPCR using PB cells. If the serum 
tryptase level is > 15 ng/mL and/or the KIT D816V ASO-qPCR detects the mutation, a bone 
marrow examination is recommended, including a KIT D816V ASO-qPCR. If the BM 
studies are compatible with the diagnosis SM, and the KIT D816V ASO-qPCR is positive, 
then the final diagnosis is KIT D816V+ SM. If the BM studies are compatible with the 
diagnosis SM, and the KIT D816V ASO-q(RT)PCR is negative, sequencing of the entire 
KIT gene should be considered on a BM sample, in order to determine the KIT structure in 
this D816V-negative patient. In MIS-negative patients who have a serum tryptase level < 15 
ng/mL and who are negative for the search of the KIT D816V mutant by ASO-qPCR on PB, 
we recommend to follow up the patients and to perform a BM investigation only if there is 
an increase in tryptase or clinical symptoms/signs suggesting the presence of mastocytosis. 
Otherwise, alternative explanations and differential diagnoses should be considered. ASO-
qPCR: allele specific-quantitative PCR on RNA or DNA; BM: bone marrow; CM: 
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cutaneous mastocytosis; MIS: “mastocytosis in the skin”; PB: peripheral blood; SM: 
systemic mastocytosis; sTryptase: serum total tryptase level.
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Table 1
Major characteristics of the various categories of mastocytosis, and distribution of KIT 
mutations along these categories.
Categories of disease and their 
major characteristics
Relative frequency Prognosis Type and frequency of KIT mutations/presence of 
additional genetic lesions
Pediatric mastocytosis
• Disease frequently 
limited to the skin
• Resolves at adolescence 
in most cases
++ Usually very good • 25% KIT WT{Bodemer, 2010 #96}
• 35% KIT D816V (D816I or D816Y)
{Bodemer, 2010 #96}
• 40% ECD KIT mutations{Bodemer, 2010 
#96}
Indolent Systemic Mastocytosis 
(ISM)
• Mostly chronic and 
stable evolution over 
decades
• Symptoms are mostly 
related to mediators 
released by MCs
• Progression into a more 
aggressive disease is 
very rare
++ Very good to good • > 80 % KIT D816V{Bibi, 2014 #5}
• A few patients are KIT WT or may present 
non codon 816 KIT mutations{Garcia-
Montero, 2006 #1665;Orfao, 2007 
#129;Bibi, 2014 #5}
• The presence of the KIT D816V mutation 
in non-MC lineages appears to be a 
predictor for risk of 
progression{Escribano, 2009 
#419;Teodosio, 2012 #66}
Smoldering Systemic Mastocytosis
• Stable evolution over 
years or decades
• Presence of a high MC 
burden in the BM
• Presence of borderline 
begin symptoms (B-
findings)*
• Some patients may 
progress to more 
aggressive disease
+ Relatively good • > 80 % KIT D816V{Arock, 2010 #80}
• Additional genetic non-KIT lesions may be 
acquired during the evolution if the patient 
progresses to a more aggressive 
disease{Bibi, 2014 #5}
Aggressive Systemic Mastocytosis 
(ASM)
• Presence of clinical signs 
related to organ 
dysfunction linked to 
MC infiltration (C-
findings)**
• Can transform into MCL
+/− Poor • > 70% KIT D816V{Arock, 2010 #80}
• A few patients may present non codon 816 
KIT mutations{Arock, 2010 #80}
• Additional genetic non-KIT lesions can be 
found {Bibi, 2014 #5}
Systemic mastocytosis with an 
Associated Hematological non MC 
disease (SM-AHNMD)
• SM part can be indolent 
or aggressive
• AHNMD component is 
mostly a myeloid 
neoplasm
+ Depending on the 
type of SM and on 
the prognosis of the 
AHNMD
• > 80% KIT D816V{Arock, 2010 #80}
• The AHNMD may present its own 
recurrent genetic lesion (BCR/ABL, JAK2 
V617F,…){Hussein, 2011 #239},{Wang, 
2013 #39}
• Additional genetic non-KIT lesions can be 
found (see{Bibi, 2014 #5})
Mast Cell Leukemia (MCL) +/− Very poor • KIT D816V mutant is less frequent than in 
ISM{Georgin-Lavialle, 2013 #44}
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Categories of disease and their 
major characteristics
Relative frequency Prognosis Type and frequency of KIT mutations/presence of 
additional genetic lesions
• >20% of atypical MCs in 
the BM smears
• Presence of C-findings
• KIT mutations in ECD or JMD or no KIT 
mutations are frequent{Joris, 2012 
#1464;Georgin-Lavialle, 2012 
#63;Georgin-Lavialle, 2013 #44}
Mast Cell Sarcoma (MCS)
• Presence of very atypical 
malignant MCs in a 
solitary mass
• Progress to MCL in a 
short time period
+/−− Very poor • No KIT D816V mutation described to date
• Other non codon 816 KIT mutations can be 
found{Ryan, 2013 #45;Kim, 2013 
#42;Georgin-Lavialle, 2013 #301}
Familial mastocytosis
• Reported in more than 50 
families since the 
mid-1880s.
• Mostly indolent pediatric 
CM
+/− Usually very good • Rare somatic KIT D816V mutations 
described in a few adult-onset SM.
{Bodemer, 2010 #96;Broesby-Olsen, 2012 
#56;Zanotti, 2013 #43}
• Most cases without KIT mutations or with 
uncommon germline mutations (i.e., 
K509I, A533D, R634W, N822I, M835K, 
S849I or deletion of amino-acids 419 or 
559-560).{Zhang, 2006 #161;Wasag, 2011 
#71;Hoffmann, 2008 #497;Wohrl, 2013 
#1465;Pollard, 2014 #1674}
*
B-findings: hypercellular BM, dysplasia, organomegaly without organ failure, and high serum tryptase levels.
**C-findings: organ dysfunction, such as cytopenia (ANC<1×109/L, Hb<10 g/dL, or platelets<100×109/l), hepatomegaly with impaired liver 
function, palpable splenomegaly with signs of hypersplenism, malabsorption with significant hypoalbuminemia, significant weight loss >10% over 
the last 6months and/or large osteolyses.
AHNMD: Associated clonal hematologic non-mast cell lineage diseases; ASM: aggressive systemic mastocytosis; BM: bone marrow; CM: 
cutaneous mastocytosis; ECD: extracellular domain; ISM: indolent systemic mastocytosis; MCL: mast cell leukemia; MCS: mast cell sarcoma; 
MCs: mast cells; WT: wild type.
++: frequent; +: relatively frequent; +/−: rare; +/−− extremely rare.
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Table 2
Summarized advantages, disadvantages and sensitivity of the different tests 
recommended to detect KIT mutations at position 816.
Technique RT-PCR plus 
restriction fragment 
length 
polymorphism 
(RFLP)
Nested RT-PCR 
followed by D-
HPLC of PCR 
amplicons
PNA-mediated PCR ASO-qPCR on DNA or RNA/cDNA
Advantages -simple
-fast
-reliable
-cost-saving
-detects different 
KIT mutations at 
position 816
-allows detection of KIT 
mutations at position 816 or at 
adjacent positions
-recommended for formalin-
fixed paraffin-embedded 
tissues
-simple
-fast
-cost-saving
-highly sensitive test -quantitative: 
allows the quantification of the KIT 
D816V allele burden in blood or BM at 
diagnosis or in the follow up
Disadvantages -detects only KIT 
D816V mutant
-not quantitative
-relatively low 
sensitivity
-not quantitative
-time-consuming
-needs special 
facilities (HPLC)
-not quantitative
-intermediate sensitivity
-detects only KIT D816V mutant
-needs standardization,validation and 
harmonization
Sensitivity ± 0.05 % 0.5-1.0 % ± 0.1% ± 0.01%
ASO-qPCR: allele specific-quantitative PCR; BM: bone marrow; D-HPLC: denaturing high performance liquid chromatography; PNA-mediated 
PCR: peptide nucleic acid-mediated; PCR RT-PCR: reverse transcriptase-polymerase chain reaction.
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Table 3
Recommended use of major clinical, biological and molecular parameters/explorations 
for the diagnosis and the follow up of adult patients with SM.
Parameters/explorations Diagnosis Follow up in 
patients with 
stable SM
Follow up in case 
of (suspected) 
progression in 
SM
Follow up in during 
cytoreductive/
targeted therapy
Clinical parameters
-Careful dermatological examination (including 
Darier’s sign)
+ + a + a + b
- Palpation for hepatomegaly, splenomegaly and/or 
lymphadenopathy
+ + c + + b
- Neuropshycological evaluation + + c + +
Biological parameters
- Serum tryptase level + + c + + d
-CBC and differential + + c + +
- BM biopsy with KIT (CD117) and tryptase staining 
by IHC
+ − + +
-Cytological examination of BM smears + − + +
- CD2/CD25 on BM MCs by IHC or flow cytometry + − + +
- CD30 on BM MCs by IHC or flow cytometry + − + +
-Serum LDH + + c + +
- Serum albumin + + c + +
-Serum calcium + + c + +
- Total IgE +
-Serum alkaline phosphatase + + c + +
-Liver function tests + + c + +
-Serum β2-microglobulin + + c + +
-Urinary histamine metabolites + − − −
-Urinary PGD2 + − − −
Molecular parameters
-ASO-qPCR for KIT D816V mutation in PB + + c + + d
-ASO-qPCR for KIT D816V mutation in BM + (see Figure 3) − + + d
-KIT sequencing + (see Figure 3) − − −
-Testing for additional genetic lesions (NSG, myeloid 
gene panels)
+(if ASM/MCL 
or SM-AHNMD)
− + +
Radiographic explorations + − + +
-Computed tomography + − + +
-Ultrasonography + − + +
-Osteodensitometry (T Score by Dexa-Scan) + + + +
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ASM: aggressive systemic mastocytosis; ASO-qPCR: allele specific-quantitative PCR; BM: bone marrow; CBC: complete blood count, IHC: 
immunohistochemistry; MCL: mast cell leukemia; MCs: mast cells; MRD: minimum residual disease; NSG: nest generation sequencing; PGD2: 
prostaglandin D2; SM: systemic mastocytosis; SM-AHNMD: systemic mastocytosis with associated hematological non MC disease.
a
If skin lesions are evolutive
b
Lesions may regress upon treatment
cAt regular intervals
dUseful to appreciate the efficacy of the treatment and to evaluate the level of MRD
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